Vienna, Austria
Vienna, Austria

Time filter

Source Type

Patent
AFFiRiS AG | Date: 2015-04-29

The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with -amyloid deposition, preferably AD.


Patent
AFFiRiS AG | Date: 2015-04-29

The invention discloses aluminium oxyhydroxide for use in the treatment and prevention of AD.


Patent
AFFiRiS AG | Date: 2015-02-23

The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.


Patent
AFFiRiS AG | Date: 2017-01-04

The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.3-3 | Award Amount: 7.70M | Year: 2013

The goal of SYMPATH is to advance clinical development of therapeutic vaccines targeting -synuclein (aSyn)-driven neurodegenerative diseases (ND). It addresses Parkinsons disease (PD) and multiple system atrophy (MSA), two synucleopathies, for which no causal therapy exists. Ultimately, both lead to patient disability and death, which along with patient number (PD) and age of onset (MSA, PD) define their high medical need status. The proposed programme focuses on 2 vaccine candidates, PD01A and PD03A, delivered by the innovative AFFITOME technology. Both are peptide-protein conjugate vaccines and first-in-class candidates. They were selected to elicit antibodies neutralizing aSyn but sparing compensatory -synuclein. Pre-clinical evaluation confirmed their disease-modifying activity in various models. The unprecedented clinical approach, called TANDEM strategy, uses the synergy resulting from applying 2 vaccine candidates in 2 complementary indications linked through their pathology. TANDEM PD/MSA capitalizes on (i) excellent clinical research centres and their associated national/European networks, (ii) platform methods assessing aSyn species as candidate biomarkers and (iii) preliminary clinical experience with PD01A, the first aSyn targeting vaccine ever tested in humans. Its core is formed by 2 phase I studies testing PD01A in MSA and PD03A in PD/MSA. Importantly, trial design (duration, endpoints, vaccine dose and schedule) will ensure collection of initial biomarker data connecting clinical results of PD- and MSA trajectories. SYMPATH defines the logical next development step of both AFFITOPE vaccine candidates for synucleopathies and generates information/material (biobank) rendering them more amenable to rational drug development. Successful completion of the programme promises reaching aSyn pathology with an active vaccine as a causal therapy for PD/MSA, thus advancing one or both candidates as prime targets for product development and investment.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.2-1 | Award Amount: 7.87M | Year: 2013

Despite remarkable progress in the understanding of the molecular pathogenesis of neurodegenerative diseases (NDD), no causative or disease-modifying treatment is currently available. Aggregation of misfolded proteins are thought to play a crucial role in the pathogenesis, but attempts to exploit this knowledge for novel treatments have not been successful. Also, pathogenetically relevant biomarkers of protein aggregation are lacking. In order to overcome this critical road-block, we have assembled an interdisciplinary consortium, consisting of world-leading experts in structural biology and ligand development, multimodal neuroimaging, animal models and clinical trials to develop a novel imaging system for combined simultaneous molecular and functional imaging (PET-MRI/fMRI) for two rare diseases caused by excessive accumulation of misfolded alpha-synuclein (SYN), multiple systems atrophy (MSA) and parkinsonism caused by mutations in the alpha-synuclein gene (SNCA), which will serve as proof-of-principle models for the more common and heterogeneous NDD. With this technology we will pioneer the monitoring of protein aggregation as a biomarker for therapeutic effects in the framework of individualized causative treatment. The central aspects of the work-flow including ligand design, software development and drug trials will be driven by three highly specialized SMEs, while translation to animal models and clinical use will be implemented by top academic centers. The groundbreaking progress will include: 1. Establish a multimodal imaging algorithm based on a new PET tracer and embracing structural and functional MRI methods to yield an SYN specific tool 2. Test this multimodal, molecular neuroimaging algorithm in animal models with regard to its potential for diagnosis, mirroring the natural disease course and response to therapy 3. Translate the algorithm including the therapeutic modality (i.e. immunotherapy with PD01, NCT01568099) to the clinical setting.


Patent
AFFiRiS AG | Date: 2015-10-23

The present invention relates to a immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID NO:9).


Patent
AFFiRiS AG | Date: 2015-07-13

A method for preventing and/or treating a synucleinopathy, comprising administering a composition containing at least one mimotope of an epitope of alpha-synuclein, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).


Patent
AFFiRiS AG | Date: 2015-07-13

The present invention relates to a composition comprising at least one mimotope of an epitope of alpha-synuclein for use in a method for preventing and/or treating -amyloidoses including Alzheimers disease, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).


The present invention relates to the use of at least one compound comprising the amino acid sequence (X_(1))_(n)X_(2)X_(3)PVX_(4)X_(5)X6(X_(7))_(m)(Formula 1),whereinX_(1) is any amino acid residue,X_(2) is an amino acid residue selected from the group consisting of aspartic acid (D) and glutamic acid (E),X_(3) is any amino acid residue,X_(4) is any amino acid residue,X_(5) is an amino acid residue selected from the group consisting of proline (P) and alanine (A),X_(6) is an amino acid residue selected from the group consisting of aspartic acid (D) and glutamic acid (E),X_(7) is any amino acid residue,n and m, independently, are 0 or an integer of more than 0,and wherein the amino acid sequence according to Formula I is not identical with, or does not comprise the 8-mer polypeptide fragment of alpha-synuclein having the amino acid sequence DMPVDPDN,said compound having a binding capacity to an antibody which is specific for an epitope of alpha-synuclein comprising the amino acid sequence DMPVDPDNfor producing a medicament for preventing and/or treating synucleinopathies.

Loading AFFiRiS AG collaborators
Loading AFFiRiS AG collaborators